| Primary |
| Cardiac Failure |
30.3% |
| Hypertension |
19.4% |
| Myocardial Infarction |
6.3% |
| Myocardial Ischaemia |
4.6% |
| Atrial Fibrillation |
4.0% |
| Cardiac Failure Congestive |
3.4% |
| Cardiac Disorder |
3.1% |
| Hyperaldosteronism |
3.1% |
| Blood Pressure Abnormal |
2.9% |
| Arrhythmia |
2.6% |
| Breast Cancer |
2.3% |
| Cardiac Failure Chronic |
2.3% |
| Cardiomyopathy |
2.3% |
| Diabetes Mellitus |
2.3% |
| Cardiovascular Insufficiency |
2.0% |
| Dressler's Syndrome |
2.0% |
| Heart Failure |
2.0% |
| Adrenal Neoplasm |
1.7% |
| Congestive Cardiomyopathy |
1.7% |
| Coronary Artery Disease |
1.7% |
|
| Renal Failure Acute |
14.8% |
| Thrombocytopenia |
10.2% |
| Renal Failure |
9.3% |
| Dysphagia |
6.5% |
| Death |
5.6% |
| Cerebrovascular Accident |
4.6% |
| Hallucination |
4.6% |
| Hypertension |
4.6% |
| Unevaluable Event |
4.6% |
| Blood Pressure Increased |
3.7% |
| Epistaxis |
3.7% |
| No Adverse Event |
3.7% |
| Swelling Face |
3.7% |
| Weight Increased |
3.7% |
| Atrial Fibrillation |
2.8% |
| Diabetes Mellitus |
2.8% |
| Drug Interaction |
2.8% |
| Hepatotoxicity |
2.8% |
| Hyponatraemia |
2.8% |
| Nasopharyngitis |
2.8% |
|
| Secondary |
| Cardiac Failure |
23.9% |
| Hypertension |
14.2% |
| Product Used For Unknown Indication |
14.2% |
| Drug Use For Unknown Indication |
12.1% |
| Atrial Fibrillation |
3.9% |
| Congestive Cardiomyopathy |
3.9% |
| Myocardial Infarction |
3.9% |
| Cardiac Failure Congestive |
2.6% |
| Coronary Artery Disease |
2.6% |
| Cardiac Pacemaker Insertion |
2.1% |
| Hypercholesterolaemia |
2.1% |
| Cardiac Failure Chronic |
1.8% |
| Cardiovascular Insufficiency |
1.8% |
| Diabetes Mellitus |
1.8% |
| Thrombosis Prophylaxis |
1.8% |
| Depression |
1.6% |
| Gout |
1.3% |
| Hyperaldosteronism |
1.3% |
| Myocardial Ischaemia |
1.3% |
| Oedema Peripheral |
1.3% |
|
| Renal Failure Acute |
23.0% |
| Jaundice |
9.8% |
| Myalgia |
4.9% |
| Renal Tubular Necrosis |
4.9% |
| Syncope |
4.9% |
| Thrombocytopenia |
4.9% |
| Urethral Haemorrhage |
4.9% |
| Cerebrovascular Accident |
3.3% |
| Diabetes Mellitus |
3.3% |
| Drug Hypersensitivity |
3.3% |
| Drug Interaction |
3.3% |
| Hyperkalaemia |
3.3% |
| Hyponatraemia |
3.3% |
| Hypotension |
3.3% |
| Intentional Drug Misuse |
3.3% |
| Leukocyturia |
3.3% |
| Long Qt Syndrome |
3.3% |
| Malaise |
3.3% |
| Myocardial Infarction |
3.3% |
| Nasopharyngitis |
3.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.2% |
| Drug Use For Unknown Indication |
16.2% |
| Hypertension |
14.1% |
| Atrial Fibrillation |
6.1% |
| Cardiac Failure |
5.2% |
| Coronary Artery Disease |
4.8% |
| Diabetes Mellitus |
4.6% |
| Cardiac Disorder |
3.7% |
| Prophylaxis |
3.3% |
| Pulmonary Arterial Hypertension |
3.3% |
| Type 2 Diabetes Mellitus |
3.1% |
| Amyloidosis |
2.5% |
| Cardiac Failure Congestive |
2.0% |
| Rheumatoid Arthritis |
1.9% |
| Pain |
1.6% |
| Prostate Cancer Metastatic |
1.4% |
| Pulmonary Hypertension |
1.4% |
| Chronic Obstructive Pulmonary Disease |
1.3% |
| Myocardial Infarction |
1.3% |
| Blood Cholesterol Increased |
1.2% |
|
| Vomiting |
10.5% |
| Weight Decreased |
9.9% |
| Myocardial Infarction |
8.1% |
| Thrombocytopenia |
8.1% |
| Ventricular Tachycardia |
7.0% |
| Syncope |
6.4% |
| Weight Increased |
5.2% |
| Pyrexia |
4.7% |
| Dyspnoea |
4.1% |
| Palpitations |
4.1% |
| Deep Vein Thrombosis |
3.5% |
| Drug Ineffective |
3.5% |
| Fall |
3.5% |
| Unevaluable Event |
3.5% |
| Uveitis |
3.5% |
| Blood Glucose Increased |
2.9% |
| Cardiomyopathy |
2.9% |
| Dehydration |
2.9% |
| Diarrhoea |
2.9% |
| Loss Of Consciousness |
2.9% |
|
| Interacting |
| Hypertension |
28.6% |
| Diabetes Mellitus |
14.3% |
| Lipids Increased |
14.3% |
| Product Used For Unknown Indication |
14.3% |
| Analgesic Therapy |
7.1% |
| Gastrointestinal Disorder |
7.1% |
| Primary Hyperaldosteronism |
7.1% |
| Rheumatic Disorder |
7.1% |
|
| Vasculitic Rash |
28.6% |
| Hypertensive Crisis |
14.3% |
| Hyponatraemia |
14.3% |
| Metabolic Acidosis |
14.3% |
| Renal Failure Acute |
14.3% |
| Transaminases Increased |
14.3% |
|
